Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations
Authors:
Open Access
- 13 June 2020
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 15 (10) , 1611-1623
Abstract
No abstract availableKeywords
Funding Information
- Genentech
- Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (RP150535)
- Merck
- Bayer HealthCare
- Novartis
- University of Texas MD Anderson Cancer Center (P30 CA016672)
- Pfizer
- Bayer Corporation
- AstraZeneca
- Takeda Pharmaceutical Company
- Mayo Clinic
- Spectrum Pharmaceuticals
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Eli Lilly and Company
- Daiichi Sankyo Company
- Roche
- National Institutes of Health
- Samsung
- National Cancer Institute (R01CA169338, R01CA204302, R01CA211052, U01CA217882, U54CA224081)
- North Carolina GlaxoSmithKline Foundation
This publication has 50 references indexed in Scilit:
- Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK DependenceCancer Research, 2014
- Mapping the molecular determinants of BRAF oncogene dependence in human lung cancerProceedings of the National Academy of Sciences, 2014
- Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroupsNature Communications, 2013
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF InhibitionCancer Discovery, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF MutationsJournal of Clinical Oncology, 2011
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- Epigenetic-Genetic Interactions in theAPC/WNT, RAS/RAF, andP53Pathways in Colorectal CarcinomaClinical Cancer Research, 2008
- Mutations of the BRAF gene in human cancerNature, 2002